3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
20
Pain, Postoperative
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Neoplasms
4
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Brain Neoplasms
4
Prostatic Neoplasms
3
Myoma
3
Leiomyoma
3
Head and Neck Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Agnosia
3
Stomatitis
2
Skin Neoplasms
2
Postoperative Hemorrhage
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Hemorrhage
2
Fatigue
2
Colonic Neoplasms
2
Chronic Pain
2
Carcinoma, Hepatocellular
2
Water-Electrolyte Imbalance
1
Vulvodynia
1
Uterine Cervical Neoplasms
1
Interventions
rozanolixizumab
5
zilucoplan
4
eculizumab
4
Rituximab
4
Immunoglobulins, Intravenous
4
efgartigimod alfa
3
Tacrolimus
3
Mycophenolic Acid
3
Hizentra
3
HBM9161
3
Data Collection
2
Azathioprine
2
tofacitinib
1
telitacicept
1
ravulizumab
1
iscalimab
1
gamma-Globulins
1
apraclonidine
1
Thymectomy
1
Telemedicine
1
Sugammadex
1
Sodium Chloride
1
Pyridostigmine Bromide
1
Prednisone
1
Prednisolone
1
Plasmapheresis
1
Plasma Exchange
1
Neurofeedback
1
Neostigmine
1
Muscle Stretching Exercises
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Myasthenia Gravis
×
Sodium Chloride
×
Clear all
NCT02950155
2024-10-26
Rinomax
Karolinska Institutet
Phase 3
Completed
47 enrolled
24 charts